Loading
Tempest Therapeutics
Tempest Therapeutics is a California company developing CAR-T cell treatments, immune cells engineered to find cancer, that target two markers at once. One is made inside the body; the other, made from a patient's own cells, is being tested in multiple myeloma.
Also called: Tempest Therapeutics, Inc.
Overview
Tempest Therapeutics, Inc., of Brisbane, California, describes in its August 2026 registration statement a pipeline of chimeric antigen receptor T cell candidates. Its lead programme, TPST-4003, is a dual CD19 and BCMA in vivo CAR-T candidate for immunology and oncology. In February 2026 it acquired rights to a dual-targeting CAR-T platform including TPST-2003, an autologous CD19 and BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma and POEMS syndrome.
Headquarters
Brisbane, CA, US
Scorecard
All companies#593of 1706 companies, score 6
- targets +4
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 2 targets, 0 registry studies. Formula on the scorecards page.
Type
Biotech · TPST
Stage
Public
Website
Products
2In vivo CAR-T (dual CD19 and BCMA)
TPST-4003 is a treatment from Tempest Therapeutics meant to turn a patient's T cells into cancer-hunting CAR-T cells inside the body, aimed at two markers on B cells and plasma cells.
Autologous CAR-T (dual CD19 and BCMA)
TPST-2003 is a CAR-T cell treatment, made from a patient's own immune cells, from Tempest Therapeutics. It targets two markers and is being tested in multiple myeloma that has come back.
Notes
- Read on 4 November 2026 in the S-1 filed with the SEC on 21 August 2026, a resale registration that incorporates the annual report by reference. The filing does not give phases or trial numbers for either candidate.
Connected
7Similar pages
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, CD19, CAR-T cell therapy.
- CompanyStarna Therapeutics
Shares In vivo CAR-T, CD19.
- CompanyAzalea Therapeutics
Shares In vivo CAR-T, BCMA, CD19.
- CompanyCapstan Therapeutics
Shares In vivo CAR-T, CD19.
- CompanyPoseida Therapeutics
Shares BCMA, CD19, CAR-T cell therapy.
- CompanyKelonia Therapeutics
Shares In vivo CAR-T, BCMA, CD19.
- PersonChristof von Kalle
Shares In vivo CAR-T, CAR-T cell therapy.
- PersonMichel Sadelain
Shares In vivo CAR-T, CD19, CAR-T cell therapy.
fronts
technologies
targets
drugs
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
tempesttx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/